New Guidelines for Preemie Drug Angers Manufacturer

August 11, 2014 | Crandall & Pera Law
New Guidelines for Preemie Drug Angers Manufacturer

Scaling back use of a costly medicine given mostly to premature babies has caused a clash between the drug's manufacturer and the nation's leading pediatrician's group, according to a recent CBS News article.

The drug, sold under the brand name Synagis, guards against a common but usually mild virus that can cause serious lung problems.

New guidelines from the American Academy of Pediatrics say medical evidence shows the drug benefits few children other than very young preemies. Its new guidance recommends it only for infants born before 29 weeks, older preemies with chronic lung disease and those with certain heart problems, and certain other at-risk children younger than age 2.

Studies show the drug can slightly reduce risks for being hospitalized but doesn't shorten hospital stays or lessen chances for long-term complications or death. Advances in treatment for preemies in recent years make Synagis unnecessary for many, the academy says.

Since the drug has seen a 19 percent drop in sales over the first quarter in 2014, MedImmune and its parent company AstraZeneca have placed full-page ads in The New York Times and several other newspapers protesting pediatricians' new recommended limits. Read the full details here:

Pediatricians, MedImmune clash over costly drug for babies 

Yet another example of insurance companies attempting to practice medicine and exert control over care and medicine their insureds need. Until insurance companies are held in check, the health care system will continue to spiral out of control.

If you or a family member believe you have a medical malpractice case, contact Crandall & Pera Law today for a free case evaluationCrandall & Pera Law is available to help answer your questions and guide you in determining your next steps.